MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its fourth quarter and year-end 2023 financial results before the market opens on Thursday, March 21, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.
紐約,2024年3月7日(GLOBE NEWSWIRE)——MinK Therapeutics, Inc.(納斯達克股票代碼:INKT)是一家臨床階段的生物製藥公司,率先發現、開發和商業化治療癌症和其他免疫介導疾病的異基因、現成不變自然殺傷劑 T(inkT)細胞療法,今天宣佈,該公司將發佈2023年第四季度和年底的財務業績在2024年3月21日星期四市場開盤之前。MinK高管將在美國東部時間當天上午 8:30 主持電話會議和網絡直播,討論結果並提供公司最新情況。
Conference Call
電話會議
Dial-in numbers: 646-307-1963 (U.S. – NY), 800-715-9871 (U.S. & Canada)
撥入號碼:646-307-1963(美國 — 紐約)、800-715-9871(美國和加拿大)
Conference ID: 1391457
會議 ID:1391457
Webcast
網絡直播
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company's website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/xa2m5uy7.
電話會議的網絡直播和重播可從公司網站的活動和演示頁面上觀看,網址爲 https://investor.minktherapeutics.com/events-and-presentations 並通過 https://edge.media-server.com/mmc/p/xa2m5uy7。
About MiNK Therapeutics
關於 MinK Therapeut
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
MinK Therapeutics是一家處於臨床階段的生物製藥公司,開創了用於治療癌症和其他免疫介導疾病的異基因不變自然殺傷T(InkT)細胞療法的發現、開發和商業化。MinK正在推進原生和下一代工程InkT程序的管道,其平台旨在促進可擴展和可重複的製造,以實現現成交付。該公司總部位於紐約州紐約。欲了解更多信息,請訪問 https://minktherapeutics.com/ 或者 @MiNK_iNKT。可能對投資者很重要的信息將定期發佈在我們的網站和社交媒體渠道上。
Investor Contact
投資者聯繫人
917-362-1370
917-362-1370
Media Contact
媒體聯繫人
781-674-4428
781-674-4428
Source: MiNK Therapeutics
來源:MinK Therapeutics
譯文內容由第三人軟體翻譯。